思连康对肝硬化血浆内毒素影响的研究

目的:探讨益生菌制剂思连康治疗肝硬化内毒素血症的作用机制。方法:采用大鼠肝硬化模型,其中治疗组予以思连康液灌胃治疗,共8周,检测治疗组及对照组血浆内毒素指标;并选取70例肝硬化ChildPugh分级为B级的患者,其中治疗组口服思连康(每次两粒,每日三次)3周,观察治疗前后血浆内毒素变化。结果:思连康治疗组的肝硬化大鼠及患者血浆内毒素均明显低于对照组(p<0.05)。结论:思连康能明显降低肝硬化患者血浆内毒素水平,可作为肝硬化患者的辅助用药。

Effect of Silico on Plasma Endotoxin of Patients with Liver Cirrhosis

Objective: To investigate the effect of Silico capsule on the levels of plasma endotoxin(PET) in rats and patients with liver cirrhosis(LC). Methods: 44 rats were induced into live cirrhosis models by injecting CCl4 every 3 days for 8 weeks. 70 patients with cirrhosis of Child-Pugh B stage were observed, and 35 patients were treated by Silico capsule(2capsules, three times a day) orally for three weeks. Plasma endotoxon was detected by tachypleus amebocyte lysate(TAL) before and after the therapy. Results: The levels of endotoxin in the treatment groups were significantly lower than those in control group(P<0.05). Conclusion: Silico could reduce the level of endotoxin in the plasma of patients with liver cirrhosis , which could be used for routine auxiliary therapy of LC patients.